백신학 분야 AI : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI in vaccinology market size is expected to grow from USD 7.25 billion in 2025 to USD 9.32 billion in 2026 and is forecast to reach USD 32.67 billion by 2031 at 28.52% CAGR over 2026-2031.

This report is Segmented by Offering (Software, Services), Application (Antigen Discovery, Screening, Trial Design, Safety Prediction, Manufacturing, Supply Chain), End User (Pharma/Biotech, Academic, Cros, Government), Deployment (Cloud, On-Prem, Hybrid), Stage (Discovery, Preclinical, Clinical, and More), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are Provided in Value (USD).

Global AI In Vaccinology Market Trends and Insights

AI-Enabled Antigen Discovery Shortens Vaccine Design Cycles

The AI in vaccinology market is getting immediate support from shorter antigen identification cycles, because developers can now screen and refine targets in weeks instead of waiting through long iterative lab programs. Google DeepMind's AlphaFold work has strengthened this shift by helping researchers anticipate protein structure behavior and stability before wet-lab testing begins, which makes early design choices more informed and less repetitive. This time reduction matters because better structural prediction can remove weak candidates earlier and improve the quality of molecules that move into physical validation. The first Phase I human trial of pEVAC-PS in June 2026 showed that an AI-designed pan-Sarbecovirus antigen could reach human testing, which gave the AI in vaccinology market a visible proof point that computational design can advance into real development programs. A 2025 Nature Medicine study also showed that AI-based influenza strain selection can predict dominant circulating strains more accurately than conventional methods, which connects discovery tools directly with annual reformulation decisions in vaccine programs.

Multi-Omics Data Integration Improves Candidate Selection Accuracy

The AI in vaccinology market is also expanding because multi-omics integration gives developers a wider biological view than single-layer screening can provide. When transcriptomics, proteomics, metabolomics, epigenomics, interactomics, phosphoproteomics, glycomics, and lipidomics are analyzed together, AI systems can capture interactions that are hard to isolate through traditional workflows. A 2026 review in Frontiers in Systems Biology showed that AI applied to multi-omics data can build predictive immune response frameworks that reveal complex relationships across molecular layers. This matters for the AI in vaccinology market because candidate prioritization improves when developers can identify not only likely antigens but also the immune and formulation conditions that may shape response quality. Research from GSK and Lawrence Livermore National Laboratory in 2025 showed that machine learning for cross-reactive antigen design could outperform older combinatorial screening methods in meningococcal vaccine development. A 2026 Nature Communications study then linked multiomic analysis with glutaminolysis-dependent metabolic pathways that can support immune memory enhancement, which broadens the role of AI from target screening into response optimization.

Fragmented And Biased Immunology Datasets Limit Model Generalization

The AI in vaccinology market still faces a deep structural constraint because model quality depends on immunology data that remains uneven in coverage, quality, and regional representation. A 2026 Frontiers in Systems Biology review identified underrepresentation of Global South populations in multi-omics datasets as a critical limitation, which means predictions can reflect a narrow genetic and environmental base rather than the wider populations vaccine programs are meant to serve. The same challenge becomes harder when batch effects, inconsistent collection protocols, and multicollinearity reduce the ability to reproduce findings across cohorts. Small sample sizes and high-dimensional datasets can produce overfit models that look persuasive in silico but fail when moved into experimental screening. In the AI in vaccinology market, this problem is most damaging for rare-pathogen programs because sparse data can bias entire candidate generations and flatten performance gains that stronger algorithms should otherwise deliver.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Optimized Clinical Trial Design Reduces Failure Risk
2. Government and CEPI-Led Pandemic Preparedness Funding
3. Weak Wet-Lab Validation Pipelines Slow Commercial Translation

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software held 58.31% of revenue in 2025, which shows that the AI in vaccinology market still centers on core platforms used for epitope mapping, structural prediction, candidate ranking, and workflow integration. This lead reflects how platform vendors have moved beyond older bioinformatics tools and are now supplying systems built around proprietary training datasets, reusable model layers, and vaccine-specific development workflows. In the AI in vaccinology market, software advantage strengthens over time because every additional pathogen record, immune response datapoint, and validation outcome can improve future predictions and deepen switching costs. The segment also benefits from rising demand for tools that connect design, screening, and documentation rather than solving only one technical task. That dynamic keeps software central to the operating model of the AI in vaccinology market even as other service-based business lines expand more quickly.

Services are projected to grow at a 31.38% CAGR through 2031, which makes them the fastest-scaling offering type in the AI in vaccinology market. Growth is being supported by biotech firms, research groups, and public health agencies that need model training, annotation support, and deployment management without building full internal AI teams. The service opportunity is not limited to compute outsourcing, because applied research support and custom model development carry higher value when customers want program-specific outputs rather than generic platform access. This is especially relevant in the AI in vaccinology industry where customers often work with distinct pathogen sets, regulatory conditions, and data structures that require tailored execution. Over time, the AI in vaccinology market should keep favoring service providers that combine technical AI expertise with domain understanding in immunology, vaccine development, and quality-controlled deployment.

Antigen discovery and design accounted for 32.24% of 2025 revenue, which kept it as the largest application area in the AI in vaccinology market. Its lead reflects the maturity of reverse vaccinology pipelines and the wider use of protein language models and structural learning systems in early candidate generation. A 2025 Nature Communications study on integrating protein language and geometric deep learning models showed how AI can improve protective antigen prediction beyond conventional immunoinformatic approaches. In the AI in vaccinology market, this application remains the entry point for many customers because faster and better antigen prioritization has a clear effect on both cost and development timing. The segment also remains well funded because discovery-stage tools create downstream value for screening, preclinical work, and reformulation planning.

Clinical trial design and optimization is projected to expand at a 32.52% CAGR through 2031, which makes it the fastest-growing application in the AI in vaccinology market. The shift shows that AI value is moving from lab support into statistical design, patient segmentation, protocol refinement, and dose-related decision support. The middle sections of the pipeline, including candidate screening and safety, efficacy, and adverse event prediction, are also strengthening as more labeled outcomes become available from AI-informed programs. The AI in vaccinology market size for this application is rising because organizations now see that better trial design can reduce both failure risk and operational waste in a way that is easier to measure than some early discovery outputs. A July 2026 report from Weill Cornell Medicine reinforced this direction by showing that an AI research team system could simulate and improve clinical trials using real-world patient data.

Complete Report Scope:

• By Offering
  • Software
  • Services
• By Application
  • Antigen Discovery and Design
  • Vaccine Candidate Screening
  • Clinical Trial Design and Optimization
  • Safety, Efficacy, and Adverse Event Prediction
  • Vaccine Manufacturing Optimization
  • Supply Chain and Demand Forecasting
• By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Government and Public Health Agencies
• By Deployment Mode
  • Cloud-Based
  • On-Premise
  • Hybrid
• By Stage of Vaccinology Workflow
  • Discovery
  • Preclinical Development
  • Clinical Development
  • Manufacturing and Scale-Up
  • Post-Market Safety Surveillance
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.62% of revenue in 2025, which kept it as the largest regional block in the AI in vaccinology market. The region benefits from a dense mix of vaccine developers, AI talent, advanced research institutions, and public funding channels tied to health security and biodefense priorities. The AI in vaccinology market in North America also gains from organizations that can combine computational design with established translational and regulatory capabilities. Canada adds depth through institutions such as VIDO at the University of Saskatchewan, which received up to CAD 24 million (USD 17.6 million) at 2025 average rates, from CEPI to support global disease prevention capabilities. Mexico is still at an earlier stage, with stronger near-term relevance in logistics and immunization planning than in advanced AI-led vaccine design.

Europe remains structurally important in the AI in vaccinology market because regulatory expectations there are shaping how platforms are built, documented, and deployed. The EMA's 2024 reflection paper requires a stronger focus on transparency and explainability across medicinal product workflows, which gives Europe a significant role in setting regulator-ready design standards. In February 2026, the European Commission committed EUR 225 million (USD 243 million) at 2026 average rates, to support next-generation influenza vaccine development through HERA under the EU4Health program. Germany and the United Kingdom remain the most active European markets because they combine AI research depth, vaccine development capability, and commercial platform presence. The AI in vaccinology market share of Europe is therefore supported less by scale alone and more by its role in setting compliance and platform design norms.

Asia-Pacific is projected to grow at a 31.15% CAGR through 2031, which makes it the fastest-growing region in the AI in vaccinology market. China and South Korea are driving much of this momentum, although they are doing so through different policy, manufacturing, and public-sector channels. In February 2026, the Chinese Academy of Sciences published details on an LLM-assisted knowledge graph system for TB vaccine antigen selection that was trained on more than 77,000 PubMed records, which highlights the region's growing depth in applied AI for vaccinology. The region also benefits from stronger public-sector interest in domestic vaccine capability and local platform development. Middle East and Africa and South America remain earlier-stage opportunities where multilateral support and infrastructure capacity will matter more than platform availability through most of the forecast period.

1. AstraZeneca
2. Atomwise, Inc.
3. Benevolent AI
4. BioNTech
5. Google DeepMind
6. GlaxoSmithKline
7. Absci Corporation
8. IBM
9. Insilico Medicine
10. Johnson & Johnson
11. Merck
12. Microsoft
13. Moderna
14. NVIDIA
15. Oracle
16. Owkin
17. Pfizer
18. Recursion Pharmaceuticals
19. Sanofi
20. Generate Biomedicines

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 AI-Enabled Antigen Discovery Shortens Vaccine Design Cycles
  • 4.2.2 Multi-Omics Data Integration Improves Candidate Selection Accuracy
  • 4.2.3 AI-Optimized Clinical Trial Design Reduces Failure Risk
  • 4.2.4 Government and CEPI-Led Pandemic Preparedness Funding
  • 4.2.5 Explainable AI Becomes Essential for Regulatory Acceptance
  • 4.2.6 Model Training Demand Rises With Rare-Pathogen and Variant Surveillance
• 4.3 Market Restraints
  • 4.3.1 Fragmented and Biased Immunology Datasets Limit Model Generalization
  • 4.3.2 Weak Wet-Lab Validation Pipelines Slow Commercial Translation
  • 4.3.3 Regulatory Uncertainty Around AI-Generated Biological Evidence
  • 4.3.4 Data Sovereignty and Cross-Border Health Data Restrictions
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Offering
  • 5.1.1 Software
  • 5.1.2 Services
• 5.2 By Application
  • 5.2.1 Antigen Discovery and Design
  • 5.2.2 Vaccine Candidate Screening
  • 5.2.3 Clinical Trial Design and Optimization
  • 5.2.4 Safety, Efficacy, and Adverse Event Prediction
  • 5.2.5 Vaccine Manufacturing Optimization
  • 5.2.6 Supply Chain and Demand Forecasting
• 5.3 By End User
  • 5.3.1 Pharmaceutical and Biotechnology Companies
  • 5.3.2 Academic and Research Institutes
  • 5.3.3 Contract Research Organizations
  • 5.3.4 Government and Public Health Agencies
• 5.4 By Deployment Mode
  • 5.4.1 Cloud-Based
  • 5.4.2 On-Premise
  • 5.4.3 Hybrid
• 5.5 By Stage of Vaccinology Workflow
  • 5.5.1 Discovery
  • 5.5.2 Preclinical Development
  • 5.5.3 Clinical Development
  • 5.5.4 Manufacturing and Scale-Up
  • 5.5.5 Post-Market Safety Surveillance
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 AstraZeneca plc
  • 6.3.2 Atomwise, Inc.
  • 6.3.3 BenevolentAI
  • 6.3.4 BioNTech SE
  • 6.3.5 Google DeepMind
  • 6.3.6 GSK plc
  • 6.3.7 Absci Corporation
  • 6.3.8 IBM
  • 6.3.9 Insilico Medicine, Inc.
  • 6.3.10 Johnson and Johnson
  • 6.3.11 Merck and Co., Inc.
  • 6.3.12 Microsoft
  • 6.3.13 Moderna, Inc.
  • 6.3.14 NVIDIA Corporation
  • 6.3.15 Oracle
  • 6.3.16 Owkin
  • 6.3.17 Pfizer Inc.
  • 6.3.18 Recursion Pharmaceuticals, Inc.
  • 6.3.19 Sanofi S.A.
  • 6.3.20 Generate Biomedicines

7 Market Opportunities & Future Outlook

• 7.1 White-Space and Unmet-Need Assessment